Skip navigation
  •  Home
  • UDC 
    • Getting started
    • RUC Policies
    • FAQ
    • FAQ on Copyright
    • More information at INFOguias UDC
  • Browse 
    • Communities
    • Browse by:
    • Issue Date
    • Author
    • Title
    • Subject
  • Help
    • español
    • Gallegan
    • English
  • Login
  •  English 
    • Español
    • Galego
    • English
  
View Item 
  •   DSpace Home
  • Facultade de Ciencias da Saúde
  • Investigación (FCS)
  • View Item
  •   DSpace Home
  • Facultade de Ciencias da Saúde
  • Investigación (FCS)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Potential role of sugar transporters in cancer and their relationship with anticancer therapy

Thumbnail
View/Open
Aparicio_Potential.pdf (1.203Mb)
Use this link to cite
http://hdl.handle.net/2183/19746
Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España
Collections
  • Investigación (FCS) [1293]
Metadata
Show full item record
Title
Potential role of sugar transporters in cancer and their relationship with anticancer therapy
Author(s)
Blanco, Moisés
Figueroa, Angélica
Grande Pulido, Enrique
García Campelo, Rosario
Antón-Aparicio, Luis M.
Date
2010-06-20
Citation
Blanco Calvo M, Figueroa A, Grande Pulido E, García Campelo R, Antón Aparicio L. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010; 2010
Abstract
[Abstract] Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number of transporter proteins to introduce sugars through their plasma membrane. Cancer cells are well known to display an enhanced sugar uptake and consumption. In fact, sugar transporters are deregulated in cancer cells so they incorporate higher amounts of sugar than normal cells. In this paper, we compile the most significant data available about biochemical and biological properties of sugar transporters in normal tissues and we review the available information about sugar carrier expression in different types of cancer. Moreover, we describe the possible pharmacological interactions between drugs currently used in anticancer therapy and the expression or function of facilitative sugar transporters. Finally, we also go into the insights about the future design of drugs targeted against sugar utilization in cancer cells.
Description
Review article
Editor version
http://dx.doi.org/10.1155/2010/205357
Rights
Atribución 3.0 España
ISSN
1687-8345
1687-8337
 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsResearch GroupAcademic DegreeThis CollectionBy Issue DateAuthorsTitlesSubjectsResearch GroupAcademic Degree

My Account

LoginRegister

Statistics

View Usage Statistics
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Send Feedback